Shandong Wohua Pharmaceutical Co (SZSE:002107) Other Net Income (Loss) : ¥0.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Shandong Wohua Pharmaceutical Co Other Net Income (Loss)?

Shandong Wohua Pharmaceutical Co's Other Net Income (Loss) for the three months ended in Mar. 2024 was ¥0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.0 Mil.

Shandong Wohua Pharmaceutical Co's quarterly Other Net Income (Loss) increased from Sep. 2023 (¥-0.0 Mil) to Dec. 2023 (¥0.0 Mil) but then stayed the same from Dec. 2023 (¥0.0 Mil) to Mar. 2024 (¥0.0 Mil).

Shandong Wohua Pharmaceutical Co's annual Other Net Income (Loss) declined from Dec. 2021 (¥0.0 Mil) to Dec. 2022 (¥-0.0 Mil) but then increased from Dec. 2022 (¥-0.0 Mil) to Dec. 2023 (¥0.0 Mil).

Shandong Wohua Pharmaceutical Co Other Net Income (Loss) Historical Data

The historical data trend for Shandong Wohua Pharmaceutical Co's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Wohua Pharmaceutical Co Other Net Income (Loss) Chart

Shandong Wohua Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

Shandong Wohua Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Shandong Wohua Pharmaceutical Co Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.0 Mil.

Shandong Wohua Pharmaceutical Co Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Shandong Wohua Pharmaceutical Co's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Shandong Wohua Pharmaceutical Co (SZSE:002107) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Wohua Pharmaceutical Co Ltd (SZSE:002107) » Definitions » Other Net Income (Loss)

Traded in Other Exchanges

N/A

Address

Fushou East Street, Chuangye Building, 2F, New and High-Tech Industrial Development Zone, Huaifang, Shandong, CHN, 261011

Website

http://www.wohua.cn

Shandong Wohua Pharmaceutical Co Ltd is a China-based company specializing in the field of cardio-cerebral vascular medicine. The company's main products consist of Xinkeshu tablets for the treatment of coronary heart disease; Naoxueshu oral liquid, promoting blood circulation by removing blood stasis; Hupo Xiaoshi granules for the treatment of urethral calculus, and Yuandu granules for the treatment of influenza, among others.

Executives

Zhao Jun	Director
Liu Wen Yi	Supervisors
Zhang Fa Zhong	Supervisors
Zhang Ge	Director
Ma Xing Chen	Supervisors
Tian Kai Ji	Directors, executives
Kong Xian Jun	Supervisors

Shandong Wohua Pharmaceutical Co (SZSE:002107) Headlines

No Headlines